Titanovo Logo
Back to Cell Types

NCI-H460Homo sapiens (Human)Cancer cell line

Also known as: NCI.H460, H460, H-460, NCIH460, NCI-HUT-460, NCI-460

🤖 AI SummaryBased on 10 publications

Quick Overview

Human non-small-cell lung cancer cell line used in cancer research.

Detailed Summary

The NCI-H460 cell line is a human non-small-cell lung cancer (NSCLC) cell line derived from a pleural effusion of a patient with lung adenocarcinoma. It is widely used in cancer research for studying tumor biology, drug sensitivity, and mechanisms of resistance. This cell line has been characterized in multiple studies for its genetic and molecular profiles, including mutations in key oncogenes and tumor suppressor genes. Research on NCI-H460 has contributed to understanding the role of specific genetic alterations in cancer progression and therapeutic responses. It is also utilized in studies involving epigenetic modifications, such as DNA methylation and histone modifications, and in investigations of cancer cell metabolism and signaling pathways.

Research Applications

Cancer biologyDrug sensitivityMechanisms of resistanceEpigenetic modificationsCancer metabolismSignaling pathways

Key Characteristics

Mutations in key oncogenesTumor suppressor gene alterationsEpigenetic modificationsDrug resistance mechanisms
Generated on 6/15/2025

Basic Information

Database IDCVCL_0459
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age CategoryUnknown
SexMale

Disease Information

DiseaseLung large cell carcinoma
LineageLung
SubtypeLarge Cell Lung Carcinoma
OncoTree CodeLCLC

DepMap Information

Source TypeATCC
Source IDACH-000463_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleKRASp.Gln61His (c.183A>T)Unspecified-DOI=10.6342/NTU.2004.01000
MutationSimplePIK3CAp.Glu545Lys (c.1633G>A)Heterozygous-from parent cell line MCF-7
MutationSimpleSTK11p.Gln37Ter (c.109C>T)Homozygous-from parent cell line A549/DDP
MutationNone reportedTP53---PubMed=19787792

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,12
D10S1248
13
D12S391
21
D13S317
13
D16S539
9
D18S51
13,15
D19S433
14
D1S1656
11,14.3
D21S11
30
D22S1045
17
D2S1338
17,25
D2S441
11,11.3
D3S1358
15,18
D5S818
9,10
D7S820
9,12
D8S1179
12
DYS391
11
FGA
21,23
Penta D
11,13
Penta E
5
TH01
9.3
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer.

Ohba Y., Yamada T., Ito T., Baba Y., Baba H.

Oncol. Rep. 29:1308-1314(2013).

DOIPubMedPMC

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Establishment and characterization of a topotecan resistant non-small cell lung cancer NCI-H460/TPT10 cell line.

Lu K.W., Yang D.-H., Wurpel J.N.D., Chen Z.-S.

Front. Cell Dev. Biol. 8:607275.1-607275.10(2020).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Minna J.D., Wistuba I.I., Pertsemlidis A.

Oncotarget 9:29601-29618(2018).

DOIPubMedPMC

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

DOIPubMedPMC

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

DOIPubMedPMC

Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane.

Robison R.A., O'Neill K.L.

Onco Targets Ther. 10:1921-1932(2017).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

Mob. DNA 7:20.1-20.11(2016).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Vandesompele J.

Sci. Data 3:160052-160052(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.

Shibata H., Ito T., Baba Y., Baba H.

Oncol. Lett. 8:1025-1030(2014).

DOIPubMedPMC

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

PLoS ONE 9:E92047-E92047(2014).

DOIPubMedPMC

Characterization of H460R, a radioresistant human lung cancer cell line, and involvement of syntrophin beta 2 (SNTB2) in radioresistance.

Im C.-N., Kim B.M., Moon E.-Y., Hong D.-W., Park J.W., Hong S.H.

Genomics Inform. 11:245-253(2013).

DOIPubMedPMC

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Hirshfield K.M., Oltvai Z.N., Vazquez A.

Cancer Metab. 1:20.1-20.13(2013).

DOIPubMedPMC

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Nat. Commun. 4:2617.1-2617.13(2013).

DOIPubMedPMC

Global proteome analysis of the NCI-60 cell line panel.";

Wilhelm M., Kuster B.

Cell Rep. 4:609-620(2013).

DOIPubMed

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

Cancer Res. 73:4372-4382(2013).

DOIPubMedPMC

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

PubMed

Neuromedin B is present in lung cancer cell lines.";

Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.

Cancer Res. 52:2732s-2736s(1992).

PubMed

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

J. Natl. Cancer Inst. 83:757-766(1991).

DOIPubMed

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.

J. Natl. Cancer Inst. 82:1420-1426(1990).

DOIPubMed

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

PubMed

Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

Cancer Res. 46:798-806(1986).

PubMed

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

van Zijl P.L.

Eur. J. Cancer 31A:230-237(1995).

DOIPubMed

Alterations of integrin expression in human lung cancer.";

Takahashi T., Ueda R.

Jpn. J. Cancer Res. 84:168-174(1993).

DOIPubMedPMC

Insulin-like growth factor expression in human cancer cell lines.";

Grimley C., Battey J., Mulshine J.L., Cuttitta F.

J. Biol. Chem. 271:11477-11483(1996).

DOIPubMed

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

DOIPubMed

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Kohara H., Harada M.

Acta Med. Okayama 53:67-75(1999).

DOIPubMed

Systematic variation in gene expression patterns in human cancer cell lines.

Botstein D., Brown P.O.

Nat. Genet. 24:227-235(2000).

DOIPubMed

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

DOIPubMed

In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype.

Yoon S.-S., Ahn K.-S., Kim S.-H., Shim Y.M., Kim J.

Lung Cancer 33:221-228(2001).

DOIPubMed

Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.

Fujii Y., Takahashi T.

Am. J. Pathol. 159:1345-1352(2001).

DOIPubMedPMC

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOIPubMed

RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.

Mitsudomi T.

Int. J. Cancer 106:45-51(2003).

DOIPubMed

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Hirohashi S., Inazawa J., Imoto I.

Hum. Mol. Genet. 14:997-1007(2005).

DOIPubMed

HLA class I and II genotype of the NCI-60 cell lines.";

Morse H.C. 3rd, Stroncek D., Marincola F.M.

J. Transl. Med. 3:11.1-11.8(2005).

DOIPubMedPMC

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

Tomoda H., Yamori T., Tsuruo T.

J. Natl. Cancer Inst. 97:765-777(2005).

DOIPubMed

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mol. Cancer Ther. 5:2606-2612(2006).

DOIPubMedPMC

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Takada M., Fukuoka M., Nakagawa K.

Cancer Res. 67:2046-2053(2007).

DOIPubMed

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

DOIPubMed

DNA fingerprinting of the NCI-60 cell line panel.";

Chanock S.J., Weinstein J.N.

Mol. Cancer Ther. 8:713-724(2009).

DOIPubMedPMC

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

DOIPubMedPMC

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

J. Virol. Methods 164:116-121(2010).

DOIPubMed

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation.

Cho M.-J., Mollah M.L., Je Y.J., Kim Y.-D., Kim C.D., Lee J.-H.

Int. J. Radiat. Oncol. Biol. Phys. 77:858-866(2010).

DOIPubMed

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

DOIPubMedPMC

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Ambudkar S.V., Gottesman M.M.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).

DOIPubMedPMC

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Kong D.-X., Yamori T.

Bioorg. Med. Chem. 20:1947-1951(2012).

DOIPubMed

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

PLoS ONE 7:E31628-E31628(2012).

DOIPubMedPMC

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

Yoon C.N., Chang Y.-T.

PLoS ONE 7:E32096-E32096(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Science 336:1040-1044(2012).

DOIPubMedPMC

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

DOIPubMedPMC

Web Resources

dtp.cancer.govstrap.nci.nih.govthermofisher.comtcpaportal.org